Literature DB >> 15470035

Geranylgeraniol regulates negatively caspase-1 autoprocessing: implication in the Th1 response against Mycobacterium tuberculosis.

María T Montero1, Joaquín Matilla, Enrique Gómez-Mampaso, Miguel A Lasunción.   

Abstract

Caspase-1 is a cysteine protease composed by two 20-kDa and two 10-kDa subunits that processes pro-IL-1beta and pro-IL-18 to their mature forms. This enzyme is present in cells as a latent zymogen that becomes active through a tightly regulated proteolytic cascade. Activation is initiated by the oligomerization of an adaptor molecule, or by the formation of a multiprotein complex named inflammasome. Negative regulation of caspase-1 activation is exerted by proteins that compete with the adaptor molecule or with the inflammasome formation. We previously reported that fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, increases caspase-1 activity in PBMC. This effect was strengthened by Mycobacterium tuberculosis, rending an exacerbated IL-1beta, IL-18, and IFN-gamma production. Mevalonate, the product of 3-hydroxy-3-methylglutaryl coenzyme A reductase, is a precursor for both nonsterol isoprenoid and sterol formation. In this study, we studied the involvement of mevalonate derivatives in the regulation of caspase-1 activation. Inhibition of sterol formation by SKF-104976 or haloperidol had no effect on IL-1beta release. However, the isoprenoid geranylgeraniol prevented both caspase-1 activation and the exacerbated IL production induced by fluvastatin. This isoprenoid significantly reduced the release of IL-18 and IFN-gamma by PBMC treated with mycobacteria, even in the absence of fluvastatin. In correlation with the increased caspase-1 activity, fluvastatin stimulated the proforms cleavage, enhancing the formation of active subunit p10. Geranylgeraniol not only prevented this effect, but induced proforms accumulation. Present results suggest that, once the proteolytic cascade is initiated, geranylgeraniol may exert an additional negative regulation on caspase-1 cleavage process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15470035     DOI: 10.4049/jimmunol.173.8.4936

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Is immunity a mechanism contributing to statin-induced diabetes?

Authors:  Brandyn D Henriksbo; Jonathan D Schertzer
Journal:  Adipocyte       Date:  2015-04-20       Impact factor: 4.534

2.  Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation.

Authors:  Jin-Fu Xu; George R Washko; Kiichi Nakahira; Hiroto Hatabu; Avignat S Patel; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; Tsuneo Yamashiro; James C Ross; Raúl San José Estépar; Alejandro A Diaz; Hui-Ping Li; Jie-Ming Qu; Blanca E Himes; Carolyn E Come; Katherine D'Aco; Fernando J Martinez; MeiLan K Han; David A Lynch; James D Crapo; Danielle Morse; Stefan W Ryter; Edwin K Silverman; Ivan O Rosas; Augustine M K Choi; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2012-01-12       Impact factor: 21.405

Review 3.  Sterols and oxysterols in immune cell function.

Authors:  Nathanael J Spann; Christopher K Glass
Journal:  Nat Immunol       Date:  2013-09       Impact factor: 25.606

Review 4.  New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.

Authors:  Thomas R Hawn; Javeed A Shah; Daniel Kalman
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

5.  Host-detrimental role of Esx-1-mediated inflammasome activation in mycobacterial infection.

Authors:  Fredric Carlsson; Janice Kim; Calin Dumitru; Kai H Barck; Richard A D Carano; Mei Sun; Lauri Diehl; Eric J Brown
Journal:  PLoS Pathog       Date:  2010-05-06       Impact factor: 6.823

6.  Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells.

Authors:  Tomoharu Sugie; Kaoru Murata-Hirai; Masashi Iwasaki; Craig T Morita; Wen Li; Haruki Okamura; Nagahiro Minato; Masakazu Toi; Yoshimasa Tanaka
Journal:  Cancer Immunol Immunother       Date:  2012-11-15       Impact factor: 6.968

7.  ESX-1-dependent cytolysis in lysosome secretion and inflammasome activation during mycobacterial infection.

Authors:  Ingrid C Koo; Chen Wang; Sridharan Raghavan; J Hiroshi Morisaki; Jeffery S Cox; Eric J Brown
Journal:  Cell Microbiol       Date:  2008-06-28       Impact factor: 3.715

Review 8.  Loss of sterol metabolic homeostasis triggers inflammasomes - how and why.

Authors:  Eric V Dang; Jason G Cyster
Journal:  Curr Opin Immunol       Date:  2018-08-29       Impact factor: 7.486

Review 9.  The cholesterol pathway: impact on immunity and cancer.

Authors:  Ryan J King; Pankaj K Singh; Kamiya Mehla
Journal:  Trends Immunol       Date:  2022-01       Impact factor: 16.687

10.  The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir.

Authors:  Richard E Kast
Journal:  Chin J Cancer       Date:  2015-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.